Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-tumor vascular inhibitor plus PD-1 monoclonal antibody in metastatic/unresectable head and neck mucosal melanoma
ChiCTR2000036500Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of PD-1 Monoclonal Antibody in mucosal melanoma (MM) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective response rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on ChiCTR2000036500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036500.